# EDGAR Filing Document

**Accession Number:** 0000313216
**File Stem:** 0000313216-23-000001
**Filing Date:** 2023-1
**Character Count:** 91136
**Document Hash:** c26cc3f8fa80945cf207385d864fc909
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000313216-23-000001.hdr.sgml**: 20230130

**ACCESSION NUMBER**: 0000313216-23-000001

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230130

**FILED AS OF DATE**: 20230130

**DATE AS OF CHANGE**: 20230130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KONINKLIJKE PHILIPS NV
- **CENTRAL INDEX KEY:** 0000313216
- **STANDARD INDUSTRIAL CLASSIFICATION:** X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05146-01
- **FILM NUMBER:** 23565135

**BUSINESS ADDRESS:**
- **STREET 1:** BREITNER CENTER
- **STREET 2:** AMSTELPLEIN 2
- **CITY:** AMSTERDAM
- **STATE:** P7
- **ZIP:** 1096 BC
- **BUSINESS PHONE:** 31 20 59 77777

**MAIL ADDRESS:**
- **STREET 1:** BREITNER CENTER
- **STREET 2:** AMSTELPLEIN 2
- **CITY:** AMSTERDAM
- **STATE:** P7
- **ZIP:** 1096 BC

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KONINKLIJKE PHILIPS ELECTRONICS NV
- **DATE OF NAME CHANGE:** 19981217

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHILIPS ELECTRONICS N V
- **DATE OF NAME CHANGE:** 19930727

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHILIPS NV
- **DATE OF NAME CHANGE:** 19910903

## SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

## FORM 6-K

------

##### REPORT OF FOREIGN ISSUER
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934**

#### January 30, 2023

------

# KONINKLIJKE PHILIPS N.V.
(Exact name of registrant as specified in its charter)

------

#### Royal Philips
(Translation of registrant's name into English)

#### The Netherlands
(Jurisdiction of incorporation or organization)

#### Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *Form 20-F ☒ Form 40-F ☐*

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *Yes ☐ No ☒*

Name and address of person authorized to receive notices and communications from the Securities and Exchange Commission:

M.J. van Ginneken<br>Koninklijke Philips N.V.<br>Amstelplein 2<br>1096 BC Amsterdam – The Netherlands

This report comprises a copy of the following report:

"Philips' Fourth Quarter Results 2022", dated January 30, 2023.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 30th day of January 2023.

KONINKLIJKE PHILIPS N.V.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; */s/* M.J. van Ginneken<br>(Chief Legal Officer)

Quarterly report

# Q4 2022
![Philips shape](visual0001.jpg)

# Philips sees some improvement in Q4 2022 and takes firm actions to address operational challenges in an uncertain environment
Amsterdam, January 30, 2023

## Fourth-quarter highlights
* Group sales amounted to EUR 5.4 billion, with 3% comparable sales growth driven by component supply improvements, while Philips' supply chain conditions remain challenging

* Comparable order intake decreased 8%, due to lower demand for COVID-19-related products compared to 2021 and company actions to improve the order book margin profile

* Income from operations amounted to EUR 171 million, compared to EUR 162 million in Q4 2021

* Adjusted EBITA of EUR 651 million, or 12.0% of sales, compared to EUR 647 million, or 13.1% of sales, in Q4 2021

* Operating cash flow was EUR 540 million, compared to EUR 720 million in Q4 2021

## Full-year highlights
* Group sales amounted to EUR 17.8 billion, with a 3% comparable sales decline due to operational and supply challenges, lower sales in China, the consequences of the Respironics field action, and the Russia-Ukraine war

* Comparable order intake decreased 3% compared to 4% growth in 2021

* Income from operations amounted to a loss of EUR 1,529 million, largely due to the previously disclosed EUR 1.5 billion non-cash goodwill and R&D impairment charges, compared to income of EUR 553 million in 2021

* Adjusted EBITA of EUR 1,318 million, or 7.4% of sales, compared to EUR 2,054 million, or 12.0% of sales, in 2021

* Operating cash outflow of EUR 173 million, compared to an inflow of EUR 1,629 million in 2021

* Proposed dividend maintained at EUR 0.85 per share, to be distributed in shares 

#### **Roy Jakobs, CEO of Royal Philips:** 
"2022 has been a very difficult year for Philips and our stakeholders, and we are taking firm actions to improve our execution and step up performance with urgency. When I took over as CEO in October 2022, I said that our priorities are first to further strengthen our patient safety and quality management and address the Philips Respironics recall; second, to improve our supply chain reliability to convert our order book to sales and improve performance; and third, to simplify how we work to increase agility and productivity. This is a step-by-step improvement journey supported by our leading market positions, extended customer base, meaningful innovations, ecosystem partnerships, strong brand, and talented employees.

As we are working through the operational challenges, we progressed on our execution priorities in the fourth quarter. We provided an important and encouraging update on the complete set of test results for the first-generation DreamStation sleep therapy devices and have completed around 90% of the production for the remediation. We were able to secure more components to convert our order book into sales, although the supply chain situation remains challenging. Our order book remains strong, despite the comparable order intake decline in the quarter. The previously announced workforce reduction by 4,000 roles globally and other actions are being implemented as planned.

Today, we will present Philips' plan to create value with sustainable impact, which is based on focused organic growth to deliver patient- and people-driven innovation at scale with improved execution as key value driver, prioritizing patient safety and quality, supply chain reliability and a simplified operating model. We are confident that these measures will enable us to deliver on our purpose to improve people's health and well-being through meaningful innovation and create value for all our stakeholders."

## **Group and business segment performance** 
Sales for the Group in the quarter were EUR 5.4 billion, with 3% comparable sales growth, which was driven by improved component supplies, for example in hospital patient monitoring, image-guided therapy, and ultrasound. However, Philips' supply chain situation remains challenging, and the company anticipates further improvements to be gradual. The combined Diagnosis & Treatment and Connected Care businesses grew 5% on a comparable basis. Adjusted EBITA for the Group was EUR 651 million, or 12% of sales, due to cost inflation, partly offset by pricing and productivity measures. Philips' comparable order intake declined 8% due to lower demand for COVID-19-related acute care products compared to 2021 and company actions to improve the order book margin profile. For the full year 2022, Philips' performance was impacted by operational and supply challenges, inflationary pressures, the COVID situation in China, the consequences of the Respironics field action, and the Russia-Ukraine war. As a result, comparable sales declined 3%, and the Adjusted EBITA margin decreased to 7.4%.

The Diagnosis & Treatment businesses' comparable sales increased 5% in the quarter, driven by high-single-digit growth in Ultrasound and Image-Guided Therapy. Comparable order intake decreased 7% due to company actions to improve the order book margin profile, and on the back of 10% growth in Q4 2021. The Adjusted EBITA margin was 11.3%, which was mainly due to cost inflation, partly offset by increased sales. For the full year, the Diagnosis & Treatment businesses recorded a 1% comparable sales decline and an Adjusted EBITA margin of 8.4%.

The Connected Care businesses' comparable sales increased 5% in the quarter, driven by strong double-digit growth in Hospital Patient Monitoring. Comparable order intake decreased by 10%, mainly due to lower demand for COVID-19-related acute care products compared to 2021. The Adjusted EBITA margin increased to 12.6%, mainly due to increased sales and productivity measures, partly offset by cost inflation. For the full year, the Connected Care businesses recorded an 11% comparable sales decline, mainly due to a strong double-digit decline in Sleep & Respiratory Care, and an Adjusted EBITA margin of 2.2%.

The Personal Health businesses' comparable sales decreased by 4% in the quarter, with double-digit growth in North America more than offset by a strong double-digit decline in China. The Adjusted EBITA margin amounted to 17.0%. For the full year, comparable sales growth for the Personal Health businesses was flat, including a 2 percentage-point impact from the Russia-Ukraine war, and the Adjusted EBITA margin amounted to 14.8%.

Highlights of Philips' ongoing focus on innovation and customer partnerships in the quarter:

* Demonstrating the trust hospital leaders have in Philips' strategy and solutions to help them improve health outcomes and productivity, and deliver care that is more convenient and sustainable, Philips signed around 100 new long-term strategic partnerships with hospitals and health systems across the world in 2022.<br>

* Philips ranked as the number 1 brand in the personal health category on E-commerce platforms JD and Ali during the 'Double 11' shopping festival in China. Philips was the highest-ranked male grooming and oral healthcare brand on the key online shopping channels.<br>

* In 2022, Philips' products and solutions improved the lives of 1.8 billion people, including 200 million people in underserved communities. In addition, Philips was again recognized with the prestigious 'A' score for its climate action leadership by global environmental non-profit CDP (Carbon Disclosure Project).<br>

* Philips launched the Ultrasound Compact 5000, which is designed for portability and versatility with premium image quality and performance, to facilitate first-time-right ultrasound exams for more patients.<br>

* In 2022, Philips' Image-Guided Therapy business reached sales of over EUR 3 billion and further expanded its market leadership position leveraging the unique strengths of its successful interventional imaging systems, such as Philips Azurion, and rich portfolio of diagnostic and therapeutic devices, such as its IVUS (intravascular ultrasound) catheters. To further drive the use of these systems and devices based on clinical evidence, more than 110 clinical studies are ongoing, including the research studies conducted by the Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center with recent results that further underpinned the outcome benefits of Philips' IVUS devices.<br>

* At RSNA 2022, one of the largest radiology meetings globally, Philips featured its latest AI-powered diagnostic systems and multi-vendor workflow solutions that help reduce clinical complexity and enhance operational efficiency. This included the MR 5300 with its unique BlueSeal magnet for helium-free operations and sustainable imaging with premium image quality and lower site costs. Philips also featured its vendor-neutral, multi-modality Radiology Operations Command Center, which is a multi-site telepresence solution that provides advanced tele-acquisition capabilities and seamlessly connects imaging experts at a command center with technologists at scanning locations across an organization.

## **Philips Respironics field action for specific sleep therapy and ventilator devices** 
In December 2022, Philips provided an update on the completed set of test results for first-generation DreamStation sleep therapy devices. Around 90% of the production required for the delivery of replacement devices to patients has been completed. In order to expedite the completion of the recall, Philips Respironics will increase the proportion of new replacement devices, resulting in an increase in the field action provision by EUR 85 million.

As previously disclosed, Philips Respironics is subject to an investigation by the US Department of Justice, is a defendant in several class-action lawsuits and individual personal injury claims, and is in ongoing discussions with the FDA regarding the proposed consent decree. Given the uncertain nature of the relevant events, and of their potential financial and operational impact and associated obligations, if any, the company has not made any provisions in the accounts for these matters.

## **Outlook** 
Looking ahead, Philips expects to deliver low-single-digit comparable sales growth and high-single-digit Adjusted EBITA margin in 2023. Considering the slowing of consumer demand and a gradual improvement of the order book conversion during 2023, Philips anticipates a slow start to the year, with improvements throughout the year supported by the ongoing productivity, pricing and other actions.

This guidance excludes the impact of the ongoing discussion on the proposed consent decree beyond current assumptions (Sleep & Respiratory Care/Respironics CSGR 2023-2025 of 10%), as well as ongoing litigation and the investigation by the US Department of Justice related to the Respironics field action.

## **Dividend** 
Philips intends to submit to the 2023 Annual General Meeting of Shareholders a proposal to declare a dividend of EUR 0.85 per common share, and to distribute such dividend in shares.

## Conference call and audio webcast
Roy Jakobs, CEO, and Abhijit Bhattacharya, CFO, will host a conference call for investors and analysts at 10:00 am CET today to discuss the results and Philips' plan to create value with sustainable impact. A live webcast of the conference call will be available on the Philips Investor Relations website and can be accessed here.

# Fourth-quarter highlights

## Philips performance

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | Q4 2021 | **Q4 2022** |
| Sales | 4944 | 5422 |
| &nbsp;&nbsp;Nominal sales growth | (6)% | 10% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fntjam9826kz4o7))</sup> | (10)% | 3% |
| Comparable order intake<sup>[2](#fntn0f754559m48))</sup> | 4% | (8)% |
| Income from operations | 162 | 171 |
| &nbsp;&nbsp; *as a % of sales** | *3.3%* | *3.2%* |
| Financial expenses, net | (21) | (78) |
| Investments in associates, net of income taxes | (8) | (86) |
| Income tax (expense) benefit | 6 | (120) |
| Income from continuing operations | 139 | (113) |
| Discontinued operations, net of income taxes | 12 | 8 |
| Net income | 151 | (105) |
| Earnings per common share (EPS) |  |  |
| &nbsp;&nbsp;Income from continuing operations attributable to shareholders<sup>[3](#fntbku50995wb4s))</sup> (in EUR) - diluted | 0.16 | (0.13) |
| &nbsp;&nbsp;Adjusted income from continuing operations attributable to shareholders<sup>[3](#fntbku50995wb4s))</sup> (in EUR) - diluted<sup>[1](#fntjam9826kz4o7))</sup> | 0.57 | 0.41 |
| &nbsp;&nbsp;Net income attributable to shareholders<sup>[3](#fntbku50995wb4s))</sup> (in EUR) - diluted | 0.18 | (0.12) |
| EBITA<sup>[1](#fntjam9826kz4o7))</sup> | 230 | 301 |
| &nbsp;&nbsp; *as a % of sales** | *4.6%* | *5.5%* |
| Adjusted EBITA<sup>[1](#fntjam9826kz4o7))</sup> | 647 | 651 |
| &nbsp;&nbsp; *as a % of sales** | *13.1%* | *12.0%* |
| Adjusted EBITDA<sup>[1](#fntjam9826kz4o7))</sup> | 905 | 891 |
| &nbsp;&nbsp; *as a % of sales** | *18.3%* | *16.4%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. <sup>2)</sup> Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. <sup>3)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

* Comparable sales increased by 3%, driven by improved component supplies. The Connected Care and Diagnosis & Treatment businesses recorded mid-single-digit growth, while the Personal Health businesses posted a mid-single-digit decline.

* Comparable order intake decreased by 8%, with a double-digit decline in the Connected Care businesses, due to lower demand for COVID-19-related acute care products compared to 2021, and a high-single-digit decline in the Diagnosis & Treatment businesses, mainly due to actions to improve the order book margin profile.

* Adjusted EBITA was EUR 651 million and the margin amounted to 12.0%, mainly due to cost inflation, partly offset by pricing and productivity measures.

* Restructuring, acquisition-related and other charges amounted to EUR 350 million, compared to EUR 417 million in Q4 2021. Q4 2022 includes EUR 103 million restructuring charges, EUR 85 million for the Respironics field-action provision, EUR 63 million Respironics field-action running remediation costs, and a EUR 60 million provision for a legal matter.

* Financial income and expenses resulted in a net expense of EUR 78 million, compared to a net expense of EUR 21 million in Q4 2021. Q4 2022 includes lower gains on the value of Philips' minority participations and higher interest expense, primarily due to bonds issued in April 2022, compared to Q4 2021.

* Investments in associates mainly includes an impairment of EUR 66 million.

* Income tax expense increased by EUR 126 million year-on-year, mainly due to lower tax benefits in Q4 2022.

* Net income in Q4 2022 decreased compared to Q4 2021, mainly due to the factors highlighted above and impairments of goodwill and technology assets of in total EUR 49 million.

#### Sales per geographic cluster
in millions of EUR unless otherwise stated

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | | | &nbsp;&nbsp;**% change** | &nbsp;&nbsp;**% change** |
| | <br>Q4 2021 | <br>**Q4 2022** | **nominal** | **comparable<sup>[1](#fnt57zc1dnk2a43))</sup>** |
| Western Europe | 1111 | 1144 | 3% | 4% |
| North America | 1903 | 2283 | 20% | 5% |
| Other mature geographies | 449 | 471 | 5% | 10% |
| Total mature geographies | 3463 | 3898 | 13% | 6% |
| Growth geographies | 1481 | 1524 | 3% | (2)% |
| **Philips Group** | **4944** | **5422** | **10%** | **3%** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

Amounts may not add up due to rounding

* Sales in mature geographies increased by 6%, driven by mid-single-digit growth in North America and Western Europe and double-digit growth in other mature geographies. In growth geographies, sales decreased by 2% on a comparable basis, mainly due to China.

#### Cash and cash equivalents balance
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | Q4 2021 | **Q4 2022** |
| **Beginning cash balance** | **3827** | **776** |
| Free cash flow<sup>[1](#fnt450c1ig007yp))</sup> | 519 | 303 |
| &nbsp;&nbsp;*Net cash flows from operating activities* | *720* | *540* |
| &nbsp;&nbsp;*Net capital expenditures* | *(201)* | *(237)* |
| Other cash flows from investing activities | (13) | 25 |
| Treasury shares transactions | (1449) | (140) |
| Changes in debt | (33) | 240 |
| Other cash flow items | 16 | (60) |
| Net cash flows from discontinued operations | (564) | 28 |
| **Ending cash balance** | **2303** | **1172** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Net cash flows from operating activities decreased, mainly due to increased working capital and cash costs related to provisions. 

* Treasury shares transactions mainly includes share repurchases for capital reduction and for Long-Term Incentive purposes, whereas Q4 2021 mainly included share repurchases for capital reduction purposes.

* Changes in debt in Q4 2022 includes the draw-down of EUR 500 million under the new EUR 1 billion credit facility that was announced in October 2022, partly offset by a commercial paper repayment of EUR 200 million.

* Net cash flows from discontinued operations in Q4 2021 included the tax payments on the sale of the Domestic Appliances business.

#### Composition of net debt to group equity<sup>1)</sup>
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | September 30, 2022 | **December 31, 2022** |
| Long-term debt | 6910 | 7270 |
| Short-term debt | 1397 | 931 |
| **Total debt** | **8307** | **8201** |
| Cash and cash equivalents | 776 | 1172 |
| **Net debt** | **7531** | **7028** |
| Shareholders' equity | 14437 | 13249 |
| Non-controlling interests | 43 | 34 |
| **Group equity** | **14479** | **13283** |
| **Net debt : group equity ratio<sup>[1](#fnt366qp480t0pb))</sup>** | **34:66** | **35:65** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

# Performance per segment

## Diagnosis & Treatment businesses

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | Q4 2021 | **Q4 2022** |
| Sales | 2508 | 2808 |
| Sales growth |  |  |
| &nbsp;&nbsp;Nominal sales growth | 2% | 12% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fnti4j5x012u2sc))</sup> | 0% | 5% |
| Income from operations | 315 | 158 |
| &nbsp;&nbsp; *as a % of sales** | *12.6%* | *5.6%* |
| EBITA<sup>[1](#fnti4j5x012u2sc))</sup> | 339 | 233 |
| &nbsp;&nbsp; *as a % of sales** | *13.5%* | *8.3%* |
| Adjusted EBITA<sup>[1](#fnti4j5x012u2sc))</sup> | 325 | 318 |
| &nbsp;&nbsp; *as a % of sales** | *13.0%* | *11.3%* |
| Adjusted EBITDA<sup>[1](#fnti4j5x012u2sc))</sup> | 406 | 395 |
| &nbsp;&nbsp; *as a % of sales** | *16.2%* | *14.1%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Comparable sales increased by 5% in Q4 2022, driven by high-single-digit growth in Ultrasound and Image-Guided Therapy, due to improved component supplies. Diagnostic Imaging recorded low-single-digit growth. 

* Comparable sales in mature geographies showed mid-single-digit growth, driven by high-single-digit growth in Western Europe and low-single-digit growth in North America. Growth geographies recorded high-single-digit growth, driven by double-digit growth in Latin America, Africa and India, partly offset by a mid-single-digit decline in China. 

* Adjusted EBITA was EUR 318 million and the margin amounted to 11.3%, mainly due to cost inflation, partly offset by increased sales.

* Restructuring, acquisition-related and other charges amounted to EUR 85 million, compared to a net gain of EUR 15 million in Q4 2021. Q4 2022 includes a provision of EUR 60 million for a legal matter and EUR 25 million restructuring and acquisition-related costs. In Q1 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 30 million. 

## Connected Care businesses

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | Q4 2021 | **Q4 2022** |
| Sales | 1199 | 1368 |
| Sales growth |  |  |
| &nbsp;&nbsp;Nominal sales growth | (24)% | 14% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fnt69v51r5wmoj9))</sup> | (32)% | 5% |
| Income from operations | (314) | (77) |
| &nbsp;&nbsp; *as a % of sales** | *(26.2)%* | *(5.6)%* |
| EBITA<sup>[1](#fnt69v51r5wmoj9))</sup> | (275) | (29) |
| &nbsp;&nbsp; *as a % of sales** | *(22.9)%* | *(2.1)%* |
| Adjusted EBITA<sup>[1](#fnt69v51r5wmoj9))</sup> | 145 | 172 |
| &nbsp;&nbsp; *as a % of sales** | *12.1%* | *12.6%* |
| Adjusted EBITDA<sup>[1](#fnt69v51r5wmoj9))</sup> | 200 | 218 |
| &nbsp;&nbsp; *as a % of sales** | *16.7%* | *15.9%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Comparable sales increased by 5%, driven by strong double-digit growth in Hospital Patient Monitoring.

* Comparable sales in growth geographies showed high-single-digit growth, driven by high-single-digit growth in China and double-digit growth in Middle East & Turkey. Mature geographies recorded mid-single-digit growth, driven by high-single-digit growth in Western Europe and low-single-digit growth in North America.

* Adjusted EBITA improved to EUR 172 million and the margin amounted to 12.6%, mainly due to increased sales and productivity measures, partly offset by cost inflation.

* Restructuring, acquisition-related and other charges were EUR 201 million, compared to EUR 420 million in Q4 2021. Q4 2022 includes EUR 85 million for the Respironics field-action provision, EUR 63 million Respironics field-action running remediation costs, and EUR 43 million restructuring and acquisition-related charges. In Q1 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 95 million. This excludes the impact of the ongoing discussion on the proposed consent decree, as well as ongoing litigation and the investigation by the US Department of Justice related to the Respironics field action.

## Personal Health businesses

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | Q4 2021 | **Q4 2022** |
| Sales | 1051 | 1056 |
| Sales growth |  |  |
| &nbsp;&nbsp;Nominal sales growth | (2)% | 0% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fnt32067x10b9lw))</sup> | (4)% | (4)% |
| Income from operations | 220 | 173 |
| &nbsp;&nbsp; *as a % of sales** | *20.9%* | *16.4%* |
| EBITA<sup>[1](#fnt32067x10b9lw))</sup> | 223 | 177 |
| &nbsp;&nbsp; *as a % of sales** | *21.2%* | *16.8%* |
| Adjusted EBITA<sup>[1](#fnt32067x10b9lw))</sup> | 222 | 180 |
| &nbsp;&nbsp; *as a % of sales** | *21.1%* | *17.0%* |
| Adjusted EBITDA<sup>[1](#fnt32067x10b9lw))</sup> | 253 | 208 |
| &nbsp;&nbsp; *as a % of sales** | *24.1%* | *19.7%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Comparable sales declined by 4%, with low-single-digit growth in Oral Healthcare, which was more than offset by a double-digit decline in Personal Care. 

* Comparable sales in mature geographies showed high-single-digit growth, driven by double-digit growth in North America and low-single-digit growth in Western Europe. Growth geographies recorded a double-digit decline, due to a double-digit decline in China and Russia & Central Asia. 

* Adjusted EBITA was EUR 180 million and the margin amounted to 17.0%, mainly due to a decline in sales and factory coverage, partly offset by productivity measures.

* In Q1 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 5 million. 

## Other

#### Key data
in millions of EUR

---

| | | |
|:---|:---|:---|
| | Q4 2021 | **Q4 2022** |
| Sales | 186 | 190 |
| Income from operations | (59) | (82) |
| EBITA<sup>[1](#fnto1vxk11s3du5))</sup> | (57) | (80) |
| Adjusted EBITA<sup>[1](#fnto1vxk11s3du5))</sup> of: | (44) | (20) |
| &nbsp;&nbsp;*IP Royalties* | *64* | *109* |
| &nbsp;&nbsp;*Innovation* | *(43)* | *(45)* |
| &nbsp;&nbsp;*Central costs* | *(62)* | *(73)* |
| &nbsp;&nbsp;*Other* | *(3)* | *(11)* |
| Adjusted EBITDA<sup>[1](#fnto1vxk11s3du5))</sup> | 45 | 70 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Sales increased by EUR 4 million, mainly due to higher royalty income, partly offset by a decrease in supplies to the divested Domestic Appliances business.

* Adjusted EBITA increased by EUR 24 million, mainly due to higher royalty income, partly offset by an adverse currency impact.

* Restructuring, acquisition-related and other charges amounted to EUR 60 million, compared to EUR 14 million in Q4 2021. Q4 2022 includes EUR 38 million restructuring charges and EUR 21 million impairment of intangible assets. In Q1 2023, restructuring, acquisition-related and other charges are expected to total approximately EUR 35 million.

# Proposed dividend distribution
A proposal will be submitted to the Annual General Meeting of Shareholders, to be held on May 9, 2023, to declare a distribution of EUR 0.85 per common share, in common shares, against retained earnings.

If the above dividend proposal is adopted, the shares will be traded ex-dividend as of May 11, 2023, at the New York Stock Exchange and Euronext Amsterdam. In compliance with the listing requirements of the New York Stock Exchange and Euronext Amsterdam, the dividend record date will be May 12, 2023.

The number of share dividend rights entitled to one new common share will be determined based on the volume-weighted average price of all traded common shares of Koninklijke Philips N.V. at Euronext Amsterdam on May 11, 12 and 15, 2023. The company will calculate the number of share dividend rights entitled to one new common share (the ratio), such that the gross dividend in shares will be approximately equal to EUR 0.85. The ratio and the number of shares to be issued will be announced on May 17, 2023. Distribution of the dividend (up to EUR 751 million), with delivery of new common shares and settlement of any fractions in cash, will take place from May 18, 2023.

Further details will be given in the agenda with explanatory notes for the 2023 Annual General Meeting of Shareholders. All information included here remains provisional until then.

# Full-year highlights

## Philips performance

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| Sales | 17156 | 17827 |
| &nbsp;&nbsp;Nominal sales growth | (1)% | 4% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fnt43n4bzvqjta1))</sup> | (1)% | (3)% |
| Comparable order intake<sup>[2](#fnthz1c06vw7s2t))</sup> | 4% | (3)% |
| Income from operations | 553 | (1529) |
| &nbsp;&nbsp; *as a % of sales* | 3.2% | (8.6)% |
| Financial expenses, net | (39) | (200) |
| Investments in associates, net of income taxes | (4) | (2) |
| Income tax (expense) benefit | 103 | 113 |
| Income from continuing operations | 612 | (1618) |
| Discontinued operations, net of income taxes | 2711 | 13 |
| Net income | 3323 | (1605) |
| Earnings per common share (EPS) |  |  |
| &nbsp;&nbsp;Income from continuing operations to shareholders<sup>[3](#fnt1odr0t73x6k1))</sup> (in EUR) - diluted | 0.67 | (1.84) |
| &nbsp;&nbsp;Adjusted income from continuing operations attributable to shareholders<sup>[3](#fnt1odr0t73x6k1))</sup> (in EUR) - diluted<sup>[1](#fnt43n4bzvqjta1))</sup> | 1.65 | 0.96 |
| &nbsp;&nbsp;Net income attributable to shareholders<sup>[3](#fnt1odr0t73x6k1))</sup> per common share (in EUR) - diluted | 3.65 | (1.82) |
| EBITA<sup>[1](#fnt43n4bzvqjta1))</sup> | 890 | 192 |
| &nbsp;&nbsp; *as a % of sales* | 5.2% | 1.1% |
| Adjusted EBITA<sup>[1](#fnt43n4bzvqjta1))</sup> | 2054 | 1318 |
| &nbsp;&nbsp; *as a % of sales* | 12.0% | 7.4% |
| Adjusted EBITDA<sup>[1](#fnt43n4bzvqjta1))</sup> | 2985 | 2305 |
| &nbsp;&nbsp; *as a % of sales* | 17.4% | 12.9% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. <sup>2)</sup> Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. <sup>3)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

* Comparable sales declined by 3%, mainly due to operational and supply challenges, the COVID situation in China, the consequences of the Respironics field action, and the Russia-Ukraine war. Comparable sales showed a low-single-digit decline in the Diagnosis & Treatment businesses, a double-digit decline in the Connected Care businesses, and flat growth in the Personal Health businesses. 

* Comparable order intake decreased by 3%, with low-single-digit growth in the Diagnosis & Treatment businesses, which was more than offset by a double-digit decline in the Connected Care businesses.

* Adjusted EBITA was EUR 1,318 million and the margin amounted to 7.4%, mainly due to the decline in sales and cost inflation, partly offset by pricing and productivity measures.

* Income from operations includes a charge of EUR 1.5 billion related to goodwill and R&D impairments.

* Restructuring, acquisition-related and other charges amounted to EUR 1,127 million, compared to EUR 1,164 million in 2021. 2022 includes: restructuring charges amounting to EUR 185 million; EUR 282 million portfolio realignment impairments and charges; EUR 250 million for the Respironics field-action provision; EUR 210 million Respironics field-action running remediation costs; a EUR 60 million provision for a legal matter; and EUR 59 million for provisions for quality actions in Connected Care.

* Financial income and expenses resulted in a net expense of EUR 200 million, compared to a net expense of EUR 39 million in 2021. 2022 includes lower gains on the value of Philips' minority participations and higher interest expense, primarily due to bonds issued in April 2022, compared to 2021.

* Income tax expense decreased by EUR 10 million year-on-year, mainly due to lower income, partly offset by a non-deductible goodwill impairment in the Sleep & Respiratory Care business in 2022 and a one-off benefit relating to the recognition of tax assets due to a business transfer in 2021.

* Net income in 2022 decreased compared to 2021, mainly due to the factors highlighted above and the EUR 2.5 billion gain on the sale of Domestic Appliances in 2021.<br>

#### Cash and cash equivalents balance
in millions of EUR

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| **Beginning cash and cash equivalents balance** | 3226 | 2303 |
| Free cash flow<sup>[1](#fntk5elnar4c7ta))</sup> | 900 | (961) |
| &nbsp;&nbsp;Net cash flows from operating activities | 1629 | (173) |
| &nbsp;&nbsp;Net capital expenditures | (729) | (788) |
| Other cash flows from investing activities | (2943) | (698) |
| Treasury shares transactions | (1613) | (174) |
| Changes in debt | (251) | 1092 |
| Dividend paid to shareholders | (482) | (412) |
| Other cash flow items | 62 | 34 |
| Net cash flows discontinued operations | 3403 | (12) |
| **Ending cash and cash equivalents balance** | **2303** | **1172** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Net cash flows from operating activities decreased, mainly due to lower cash earnings, increased working capital and cash costs related to the Philips Respironics field action.

* Other cash flows from investing activities mainly includes the acquisitions of Vesper Medical and Cardiologs, whereas 2021 included the acquisitions of BioTelemetry and Capsule Technologies.

* Treasury shares transactions mainly includes share repurchases for capital reduction and for Long-Term Incentive purposes, whereas 2021 mainly included share repurchases for capital reduction purposes.

* Changes in debt in 2022 mainly includes new bonds issued of EUR 2 billion and the draw-down of EUR 500 million under the new EUR 1 billion credit facility, partly offset by bond repayments of EUR 1.2 billion.

* Net cash flows from discontinued operations in 2021 included the net cash proceeds after tax on the sale of the Domestic Appliances business.

#### Composition of net debt to group equity<sup>1)</sup>
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
| | December 31, 2021 | **December 31, 2022** |
| Long-term debt | 6473 | 7270 |
| Short-term debt | 506 | 931 |
| **Total debt** | **6980** | **8201** |
| Cash and cash equivalents | 2303 | 1172 |
| **Net debt** | **4676** | **7028** |
| Shareholders' equity | 14438 | 13249 |
| Non-controlling interests | 36 | 34 |
| **Group equity** | **14475** | **13283** |
| **Net Debt : group equity ratio<sup>[1](#fntwn296u58163z))</sup>** | 24:76 | 35:65 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* The increase in net debt to group equity in 2022 mainly results from new bonds issued, net cash outflow and the effect of the net loss, partly offset by currency translation gains in equity.

# Performance per segment

## Diagnosis & Treatment businesses

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| Sales | 8635 | 9168 |
| Sales growth |  |  |
| &nbsp;&nbsp;Nominal sales growth | 6% | 6% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fnt08096ihc40nr))</sup> | 8% | (1)% |
| Income from operations | 941 | 404 |
| &nbsp;&nbsp; *as a % of sales* | 10.9% | 4.4% |
| EBITA<sup>[1](#fnt08096ihc40nr))</sup> | 1097 | 573 |
| &nbsp;&nbsp; *as a % of sales* | 12.7% | 6.2% |
| Adjusted EBITA<sup>[1](#fnt08096ihc40nr))</sup> | 1071 | 774 |
| &nbsp;&nbsp; *as a % of sales* | 12.4% | 8.4% |
| Adjusted EBITDA<sup>[1](#fnt08096ihc40nr))</sup> | 1358 | 1055 |
| &nbsp;&nbsp; *as a % of sales* | 15.7% | 11.5% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Comparable sales declined by 1%, with mid-single-digit growth in Image-Guided Therapy and low-single-digit growth in Enterprise Diagnostic Informatics, which was more than offset by a decline in Ultrasound and in Diagnostic Imaging due to specific electronic component shortages.

* Comparable sales growth in mature geographies was flat. Growth geographies recorded a low-single-digit decline, which was mainly due to China.

* Adjusted EBITA was EUR 774 million and the margin amounted to 8.4%, mainly due to cost inflation, partly offset by productivity measures.

* Restructuring, acquisition-related and other charges amounted to EUR 201 million, compared to a gain of EUR 25 million in 2021. 2022 includes EUR 120 million portfolio realignment impairments and charges and a provision of EUR 60 million for a legal matter.

## Connected Care businesses

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| Sales | 4573 | 4403 |
| Sales growth |  |  |
| &nbsp;&nbsp;Nominal sales growth | (17)% | (4)% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fntp650mz19qd9y))</sup> | (23)% | (11)% |
| Income from operations | (722) | (2246) |
| &nbsp;&nbsp; *as a % of sales* | (15.8)% | (51.0)% |
| EBITA<sup>[1](#fntp650mz19qd9y))</sup> | (562) | (716) |
| &nbsp;&nbsp; *as a % of sales* | (12.3)% | (16.3)% |
| Adjusted EBITA<sup>[1](#fntp650mz19qd9y))</sup> | 497 | 95 |
| &nbsp;&nbsp; *as a % of sales* | 10.9% | 2.2% |
| Adjusted EBITDA<sup>[1](#fntp650mz19qd9y))</sup> | 680 | 326 |
| &nbsp;&nbsp; *as a % of sales* | 14.9% | 7.4% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Comparable sales declined by 11%, mainly due to the consequences of the Respironics field action and the impact of supply chain headwinds.

* Comparable sales in growth geographies showed a double-digit decline and in mature geographies a high-single-digit decline.

* Adjusted EBITA was EUR 95 million and the margin amounted to 2.2%, mainly due to the decline in sales and cost inflation, partly offset by productivity measures.

* Income from operations includes a charge of EUR 1.3 billion related to a goodwill impairment due to revisions to the expected future cash flows of the Sleep & Respiratory Care business. 

* Restructuring, acquisition-related and other charges were EUR 811 million, compared to EUR 1,058 million in 2021. 2022 includes EUR 250 million for the Respironics field action provision, EUR 210 million Respironics running remediation costs, EUR 160 million portfolio realignment impairments and charges, EUR 59 million provisions for quality actions in Connected Care, and EUR 108 million restructuring and acquisition-related charges.

## Personal Health businesses

#### Key data
in millions of EUR unless otherwise stated

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| Sales | 3429 | 3626 |
| Sales growth |  |  |
| &nbsp;&nbsp;Nominal sales growth | 7% | 6% |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fntr8644y707xz3))</sup> | 9% | 0% |
| Income from operations | 576 | 515 |
| &nbsp;&nbsp; *as a % of sales* | 16.8% | 14.2% |
| EBITA<sup>[1](#fntr8644y707xz3))</sup> | 591 | 531 |
| &nbsp;&nbsp; *as a % of sales* | 17.2% | 14.6% |
| Adjusted EBITA<sup>[1](#fntr8644y707xz3))</sup> | 590 | 538 |
| &nbsp;&nbsp; *as a % of sales* | 17.2% | 14.8% |
| Adjusted EBITDA<sup>[1](#fntr8644y707xz3))</sup> | 706 | 652 |
| &nbsp;&nbsp; *as a % of sales* | 20.6% | 18.0% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Comparable sales growth was flat. Oral Healthcare and Mother & Child Care recorded mid-single-digit growth, which was offset by a mid-single-digit decline in Personal Care.

* Comparable sales in mature geographies showed high-single-digit growth, driven by double-digit growth in North America. Growth geographies recorded a double-digit decline, mainly due to China.

* Adjusted EBITA was EUR 538 million and the margin amounted to 14.8%, mainly due to cost inflation and an adverse foreign currency impact, partly offset by pricing and productivity measures.

## Other

#### Key data
in millions of EUR

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| Sales | 519 | 629 |
| Income from operations | (242) | (202) |
| EBITA<sup>[1](#fntrjj1bv52b10a))</sup> | (236) | (196) |
| Adjusted EBITA<sup>[1](#fntrjj1bv52b10a))</sup> of: | (105) | (89) |
| &nbsp;&nbsp; *IP Royalties** | *246* | *322* |
| &nbsp;&nbsp; *Innovation** | *(151)* | *(135)* |
| &nbsp;&nbsp; *Central costs** | *(189)* | *(258)* |
| &nbsp;&nbsp; *Other** | *(10)* | *(18)* |
| Adjusted EBITDA<sup>[1](#fntrjj1bv52b10a))</sup> | 241 | 272 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

* Sales increased by EUR 110 million, mainly due to additional royalty income and supplies to the divested Domestic Appliances business.

* Adjusted EBITA increased by EUR 16 million, mainly due to higher royalty income, partly offset by an adverse currency impact and investment in Quality & Regulatory.

* Restructuring, acquisition-related and other charges amounted to EUR 107 million, compared to EUR 131 million in 2021. 2022 includes EUR 61 million restructuring charges and a EUR 21 million impairment of intangible assets.

# Forward-looking statements and other important information

## Forward-looking statements
This document and the related oral presentation, including responses to questions following the presentation, contain certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about our strategy, estimates of sales growth, future Adjusted EBITA<sup>[\*](#fn2ft11l7oa38x))</sup>, future restructuring and acquisition-related charges and other costs, future developments in Philips' organic business and the completion of acquisitions and divestments. Forward-looking statements can be identified generally as those containing words such as "anticipates", "assumes", "believes", "estimates", "expects", "should", "will", "will likely result", "forecast", "outlook", "projects", "may" or similar expressions. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

These factors include but are not limited to: Philips' ability to gain leadership in health informatics in response to developments in the health technology industry; Philips' ability to transform its business model to health technology solutions and services; macroeconomic and geopolitical changes; integration of acquisitions and their delivery on business plans and value creation expectations; securing and maintaining Philips' intellectual property rights, and unauthorized use of third-party intellectual property rights; Philips' ability to meet expectations with respect to ESG-related matters; failure of products and services to meet quality or security standards, adversely affecting patient safety and customer operations; breaches of cybersecurity; Philips' ability to execute and deliver on programs on business transformation and IT system changes and continuity; the effectiveness of our supply chain; attracting and retaining personnel; COVID and other pandemics; challenges to drive operational excellence and speed in bringing innovations to market; compliance with regulations and standards including quality, product safety and (cyber) security; compliance with business conduct rules and regulations; treasury and financing risks; tax risks; reliability of internal controls, financial reporting and management process. For a discussion of factors that could cause future results to differ from such forward-looking statements, see also the Risk management chapter included in the Annual Report 2021. Reference is also made to Risk management in the Philips semi-annual report 2022.

Philips has recognized a provision related to the voluntary recall notification in the US/field safety notice outside the US for certain sleep and respiratory care products, based on Philips' best estimate for the expected field actions. Future developments are subject to significant uncertainties, which require management to make estimates and assumptions about items such as quantities and the portion to be replaced or repaired. Actual outcomes in future periods may differ from these estimates and affect the company's results of operations, financial position and cash flows. In Q3 2022 there was a goodwill impairment charge of EUR 1.3 billion related to the Sleep & Respiratory Care cash-generating unit (CGU). As a result of this impairment and related uncertainties, the valuation of the CGU remains sensitive to changes in key assumptions. Adverse changes to these assumptions would cause a material impairment loss to be recognized. Furthermore, Philips Respironics is subject to an investigation by the US Department of Justice, is a defendant in several class-action lawsuits and individual personal injury claims, and is in ongoing discussions with the FDA regarding a proposed consent decree. Given the uncertain nature of the relevant events, and of their potential financial and operational impact and associated obligations, if any, the company has not made any provisions in the accounts for these matters.

## Third-party market share data
Statements regarding market share, contained in this document, including those regarding Philips' competitive position, are based on outside sources such as specialized research institutes, industry and dealer panels in combination with management estimates. Where information is not yet available to Philips, market share statements may also be based on estimates and projections prepared by management and/or based on outside sources of information. Management's estimates of rankings are based on order intake or sales, depending on the business.

## Market Abuse Regulation
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

## Use of non-IFRS information
In presenting and discussing the Philips Group's financial position, operating results and cash flows, management uses certain non-IFRS financial measures. These non-IFRS financial measures should not be viewed in isolation as alternatives to the equivalent IFRS measure and should be used in conjunction with the most directly comparable IFRS measures. Non-IFRS financial measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of these non-IFRS measures to the most directly comparable IFRS measures is contained in this document. Further information on non-IFRS measures can be found in the Annual Report 2021.

## Use of fair value information
In presenting the Philips Group's financial position, fair values are used for the measurement of various items in accordance with the applicable accounting standards. These fair values are based on market prices, where available, and are obtained from sources that are deemed to be reliable. Readers are cautioned that these values are subject to changes over time and are only valid at the balance sheet date. When quoted prices or observable market data are not readily available, fair values are estimated using appropriate valuation models and unobservable inputs.

Such fair value estimates require management to make significant assumptions with respect to future developments, which are inherently uncertain and may therefore deviate from actual developments. Critical assumptions used are disclosed in the Annual Report 2021. In certain cases independent valuations are obtained to support management's determination of fair values.

## Presentation
All amounts are in millions of euros unless otherwise stated. Due to rounding, amounts may not add up precisely to the totals provided. All reported data is unaudited. Financial reporting is in accordance with the accounting policies as stated in the Annual Report 2021 except for the adoption of new standards and amendments to standards which are also expected to be reflected in the company's consolidated financial statements for the year ending December 31, 2022.

Prior-period amounts have been reclassified to conform to the current-period presentation due to immaterial organizational changes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>\*)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information.

# Condensed consolidated statements of income
in millions of EUR unless otherwise stated

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Q4 | Q4 | January to December | January to December |
| | 2021 | **2022** | 2021 | **2022** |
| **Sales** | **4944** | **5422** | **17156** | **17827** |
| &nbsp;&nbsp;Cost of sales | (3026) | (3201) | (9988) | (10633) |
| **Gross margin** | **1918** | **2221** | **7168** | **7194** |
| &nbsp;&nbsp;Selling expenses | (1175) | (1280) | (4258) | (4609) |
| &nbsp;&nbsp;General and administrative expenses | (124) | (195) | (599) | (671) |
| &nbsp;&nbsp;Research and development expenses | (475) | (504) | (1806) | (2103) |
| &nbsp;&nbsp;Impairment of goodwill |  | (27) | (15) | (1357) |
| &nbsp;&nbsp;Other business income | 45 | 26 | 186 | 127 |
| &nbsp;&nbsp;Other business expenses | (28) | (70) | (123) | (109) |
| **Income from operations** | **162** | **171** | **553** | **(1529)** |
| &nbsp;&nbsp;Financial income | 35 | 14 | 149 | 58 |
| &nbsp;&nbsp;Financial expenses | (56) | (92) | (188) | (258) |
| &nbsp;&nbsp;Investment in associates, net of income taxes | (8) | (86) | (4) | (2) |
| **Income before taxes** | **133** | **7** | **509** | **(1731)** |
| &nbsp;&nbsp;Income tax (expense) benefit | 6 | (120) | 103 | 113 |
| **Income from continuing operations** | **139** | **(113)** | **612** | **(1618)** |
| &nbsp;&nbsp;Discontinued operations, net of income taxes | 12 | 8 | 2711 | 13 |
| **Net income** | **151** | **(105)** | **3323** | **(1605)** |
| **Attribution of net income** |  |  |  |  |
| Net income attributable to shareholders<sup>[1](#fnts6zia250cstb))</sup> | 157 | (106) | 3319 | (1608) |
| Net income attributable to non-controlling interests | (6) | 0 | 4 | 3 |
| Income from continuing operations attributable to shareholders<sup>[1](#fnts6zia250cstb))</sup> | 145 | (113) | 608 | (1622) |
| **Earnings per common share** |  |  |  |  |
| Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands): |  |  |  |  |
| - basic | 888858 | 882867 | 904272 | 881616 |
| - diluted | 894388 | 882867 | 909655 | 881616 |
| Income from continuing operations attributable to shareholders<sup>[1](#fnts6zia250cstb))</sup> (in EUR) |  |  |  |  |
| - basic | 0.16 | (0.13) | 0.67 | (1.84) |
| - diluted | 0.16 | (0.13) | 0.67 | (1.84) |
| Net income attributable to shareholders<sup>[1](#fnts6zia250cstb))</sup> (in EUR) |  |  |  |  |
| - basic | 0.18 | (0.12) | 3.67 | (1.82) |
| - diluted | 0.18 | (0.12) | 3.65 | (1.82) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

Amounts may not add up due to rounding.

# Condensed statements of comprehensive income
In millions of EUR

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| **Net income for the period** | **3323** | **(1605)** |
| Pensions and other post employment plans: |  |  |
| &nbsp;&nbsp;Remeasurement, before tax | 134 | 101 |
| &nbsp;&nbsp;Income tax effect on remeasurements | (21) | (20) |
| Financial assets fair value through OCI: |  |  |
| &nbsp;&nbsp;Net current-period change, before tax | (39) | (32) |
| &nbsp;&nbsp;Income tax effect on net current-period change | 1 | 1 |
| **Total of items that will not be reclassified to Income statement** | **74** | **49** |
| Currency translation differences: |  |  |
| &nbsp;&nbsp;Net current-period change, before tax | 1078 | 748 |
| &nbsp;&nbsp;Income tax effect on net current-period change | (5) | 2 |
| &nbsp;&nbsp;Reclassification adjustment for (gain) loss realized | 36 | - |
| &nbsp;&nbsp;Reclassification adjustment for (gain) loss realized, in discontinued operations | 69 |  |
| Cash flow hedges: |  |  |
| &nbsp;&nbsp;Net current-period change, before tax | (52) | (29) |
| &nbsp;&nbsp;Income tax effect on net current-period change | 18 | (10) |
| &nbsp;&nbsp;Reclassification adjustment for (gain) loss realized | (14) | 63 |
| **Total of items that are or may be reclassified to Income Statement** | **1129** | **774** |
| **Other comprehensive income for the period** | **1203** | **823** |
| **Total comprehensive income for the period** | **4527** | **(782)** |
| Total comprehensive income (loss) attributable to: |  |  |
| &nbsp;&nbsp;Shareholders of Koninklijke Philips N.V. | 4520 | (786) |
| &nbsp;&nbsp;Non-controlling interests | 7 | 4 |

---

Amounts may not add up due to rounding.

# Condensed consolidated balance sheets
in millions of EUR

---

| | | |
|:---|:---|:---|
| | December 31, 2021 | **December 31, 2022** |
| **Non-current assets:** |  |  |
| &nbsp;&nbsp;Property, plant and equipment | 2699 | 2638 |
| &nbsp;&nbsp;Goodwill | 10637 | 10238 |
| &nbsp;&nbsp;Intangible assets excluding goodwill | 3650 | 3526 |
| &nbsp;&nbsp;Non-current receivables | 224 | 279 |
| &nbsp;&nbsp;Investments in associates | 426 | 537 |
| &nbsp;&nbsp;Other non-current financial assets | 630 | 660 |
| &nbsp;&nbsp;Non-current derivative financial assets | 2 | 4 |
| &nbsp;&nbsp;Deferred tax assets | 2216 | 2449 |
| &nbsp;&nbsp;Other non-current assets | 129 | 98 |
| **Total non-current assets** | **20613** | **20429** |
| **Current assets:** |  |  |
| &nbsp;&nbsp;Inventories | 3450 | 4049 |
| &nbsp;&nbsp;Other current financial assets | 2 | 11 |
| &nbsp;&nbsp;Other current assets | 493 | 490 |
| &nbsp;&nbsp;Current derivative financial assets | 61 | 123 |
| &nbsp;&nbsp;Income tax receivable | 180 | 222 |
| &nbsp;&nbsp;Current receivables | 3787 | 4115 |
| &nbsp;&nbsp;Assets classified as held for sale | 71 | 77 |
| &nbsp;&nbsp;Cash and cash equivalents | 2303 | 1172 |
| **Total current assets** | **10347** | **10259** |
| **Total assets** | **30961** | **30688** |
| **Equity:** |  |  |
| &nbsp;&nbsp;Equity | 14438 | 13249 |
| &nbsp;&nbsp;&nbsp;&nbsp; *Common shares** | *177* | *178* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Capital in excess of par value* | *4646* | *5025* |
| &nbsp;&nbsp;&nbsp;&nbsp; *Reserves** | *748* | *1488* |
| &nbsp;&nbsp;&nbsp;&nbsp; *Other** | *8868* | *6558* |
| &nbsp;&nbsp;Non-controlling interests | 36 | 34 |
| **Group equity** | **14475** | **13283** |
| **Non-current liabilities:** |  |  |
| &nbsp;&nbsp;Long-term debt | 6473 | 7270 |
| &nbsp;&nbsp;Non-current derivative financial liabilities | 119 | 4 |
| &nbsp;&nbsp;Long-term provisions | 1315 | 1097 |
| &nbsp;&nbsp;Deferred tax liabilities | 83 | 91 |
| &nbsp;&nbsp;Non-current contract liabilities | 446 | 515 |
| &nbsp;&nbsp;Non-current tax liabilities | 544 | 435 |
| &nbsp;&nbsp;Other non-current liabilities | 56 | 60 |
| **Total non-current liabilities** | **9037** | **9471** |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;Short-term debt | 506 | 931 |
| &nbsp;&nbsp;Current derivative financial liabilities | 83 | 207 |
| &nbsp;&nbsp;Income tax payable | 128 | 40 |
| &nbsp;&nbsp;Accounts payable | 1872 | 1968 |
| &nbsp;&nbsp;Accrued liabilities | 1784 | 1626 |
| &nbsp;&nbsp;Current contract liabilities | 1491 | 1696 |
| &nbsp;&nbsp;Short-term provisions | 998 | 1018 |
| &nbsp;&nbsp;Liabilities directly associated with assets held for sale | 1 | - |
| &nbsp;&nbsp;Other current liabilities | 587 | 448 |
| **Total current liabilities** | **7450** | **7934** |
| **Total liabilities and group equity** | **30961** | **30688** |

---

Amounts may not add up due to rounding.

# Consolidated statements of cash flows
in millions of EUR

---

| | | |
|:---|:---|:---|
|  | January to December | January to December |
| | 2021 | **2022** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;Net income (loss) | 3323 | (1605) |
| &nbsp;&nbsp;Results of discontinued operations - net of income tax | (2711) | (13) |
| &nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by (used for) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation, amortization and impairment of assets | 1323 | 1602 |
| &nbsp;&nbsp;&nbsp;&nbsp;Impairment of goodwill | 15 | 1357 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 108 | 95 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss (gain) on sale of assets | 55 | (115) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | (18) | (25) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense on debt, borrowings and other liabilities | 152 | 226 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments in associates, net of income taxes | 4 | 112 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (103) | (113) |
| &nbsp;&nbsp;Decrease (increase) in working capital: | (401) | (862) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Decrease (increase) in receivables and other current assets* | (39) | (342) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Decrease (increase) in inventories* | (581) | (572) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Increase (decrease) in accounts payable, accrued and other current liabilities* | 219 | 52 |
| &nbsp;&nbsp;Decrease (increase) in non-current receivables and other assets | (46) | 1 |
| &nbsp;&nbsp;Increase (decrease) in other liabilities | 33 | (84) |
| &nbsp;&nbsp;Increase (decrease) in provisions | 427 | (199) |
| &nbsp;&nbsp;Other items | (164) | (39) |
| &nbsp;&nbsp;Interest received | 17 | 15 |
| &nbsp;&nbsp;Interest paid | (151) | (205) |
| &nbsp;&nbsp;Dividends received from investments in associates | 14 | 12 |
| &nbsp;&nbsp;Income taxes paid | (249) | (333) |
| **Net cash provided by (used for) operating activities** | **1629** | **(173)** |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;Net capital expenditures | (729) | (788) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Purchase of intangible assets* | (107) | (105) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Expenditures on development assets* | (259) | (257) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Capital expenditures on property, plant and equipment* | (397) | (444) |
| &nbsp;&nbsp;&nbsp;&nbsp; *Proceeds from sales of property, plant and equipment* | 33 | 18 |
| &nbsp;&nbsp;Net proceeds from (cash used for) derivatives and current financial assets | 48 | (72) |
| &nbsp;&nbsp;Purchase of other non-current financial assets | (124) | (116) |
| &nbsp;&nbsp;Proceeds from other non-current financial assets | 124 | 78 |
| &nbsp;&nbsp;Purchase of businesses, net of cash acquired | (3098) | (712) |
| &nbsp;&nbsp;Net proceeds from sale of interests in businesses, net of cash disposed of | 107 | 124 |
| **Net cash provided by (used for) investing activities** | **(3672)** | **(1487)** |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;Proceeds from issuance of (payments on) short-term debt | (25) | 47 |
| &nbsp;&nbsp;Principal payments on short-term portion of long-term debt | (302) | (1472) |
| &nbsp;&nbsp;Proceeds from issuance of long-term debt | 76 | 2516 |
| &nbsp;&nbsp;Re-issuance of treasury shares | 23 | 12 |
| &nbsp;&nbsp;Purchase of treasury shares | (1636) | (187) |
| &nbsp;&nbsp;Dividend paid to shareholders<sup>[1](#fntz3r0k0jzb6xo))</sup> | (482) | (412) |
| &nbsp;&nbsp;Dividend paid to shareholders of non-controlling interests | (2) | (6) |
| **Net cash provided by (used for) financing activities** | **(2347)** | **500** |
| **Net cash provided by (used for) continuing operations** | **(4390)** | **(1160)** |
| **Net cash provided by (used for) discontinued operations** | **3403** | **(12)** |
| **Net cash provided by (used for) continuing and discontinued operations** | **(986)** | **(1172)** |
| Effect of changes in exchange rates on cash and cash equivalents | 65 | 41 |
| Cash and cash equivalents at the beginning of the period | 3226 | 2303 |
| **Cash and cash equivalents at the end of the period** | **2303** | **1172** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

For a number of reasons, principally the effects of translation differences, certain items in the statements of cash flows do not correspond to the differences between the balance sheet amounts for the respective items. Amounts may not add up due to rounding.

# Condensed consolidated statements of change in equity
In millions of EUR

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common shares<br>| Capital in excess of par value<br>| Fair value through OCI<br>| Cash flow hedges<br>| Currency translation differences<br>| Retained earnings<br>| Treasury shares at cost<br>| Total shareholders' equity<br>| Non-controlling interests<br>| Group equity<br>|
| | | | **reserves** | **reserves** | **reserves** | **other** | **other** | | | |
| **Balance as of January 1, 2021** | **182** | **4400** | **(305)** | **23** | **(58)** | **7828** | **(199)** | **11870** | **31** | **11901** |
| Total comprehensive income (loss) |  |  | (39) | (48) | 1175 | 3432 |  | 4520 | 7 | 4527 |
| Dividend distributed | 1 | 290 |  |  |  | (773) |  | (482) | (2) | (484) |
| Minority buy-out |  |  |  |  |  |  |  |  | - | - |
| Transfer of gain on disposal of equity investments at FVTOCI to retained earnings |  |  |  |  |  | - |  | - |  | - |
| Purchase of treasury shares |  |  |  |  |  | - | (758) | (757) |  | (757) |
| Re-issuance of treasury shares |  | (150) |  |  |  | 18 | 143 | 11 |  | 11 |
| Forward contracts |  |  |  |  |  | 48 | (869) | (821) |  | (821) |
| Share call options |  |  |  |  |  | 12 | (21) | (9) |  | (9) |
| Cancellation of treasury shares | (7) |  |  |  |  | (1221) | 1228 |  |  |  |
| Share-based compensation plans |  | 110 |  |  |  |  |  | 110 |  | 110 |
| Income tax share-based compensation plans |  | (4) |  |  |  |  |  | (4) |  | (4) |
| **Balance as of December 31, 2021** | **177** | **4646** | **(344)** | **(25)** | **1117** | **9344** | **(476)** | **14438** | **36** | **14475** |
|  **Balance as of January 1, 2022** | **177** | **4646** | **(344)** | **(25)** | **1117** | **9344** | **(476)** | **14438** | **36** | **14475** |
| Total comprehensive income (loss) |  |  | (32) | 23 | 749 | (1527) |  | (786) | 4 | (782) |
| Dividend distributed | 3 | 326 |  |  |  | (741) |  | (412) | (6) | (418) |
| Transfer of gain on disposal of equity investments at FVTOCI to retained earnings |  |  | (1) |  |  | 1 |  | - |  | - |
| Purchase of treasury shares |  |  |  |  |  | - | (24) | (24) |  | (24) |
| Re-issuance of treasury shares |  | (43) |  |  |  | (28) | 77 | 7 |  | 7 |
| Forward contracts |  |  |  |  |  | 76 | (140) | (64) |  | (64) |
| Share call options |  |  |  |  |  | 5 | (12) | (6) |  | (6) |
| Cancellation of treasury shares | (2) |  |  |  |  | (298) | 299 |  |  |  |
| Share-based compensation plans |  | 95 |  |  |  |  |  | 95 |  | 95 |
| Income tax share-based compensation plans |  | 1 |  |  |  |  |  | 1 |  | 1 |
| **Balance as of December 31, 2022** | **178** | **5025** | **(376)** | **(2)** | **1866** | **6832** | **(275)** | **13249** | **34** | **13283** |

---

Amounts may not add up due to rounding.

# Reconciliation of non-IFRS information
Certain non-IFRS financial measures are presented when discussing the Philips Group's performance:

* Comparable sales growth

* Adjusted income from continuing operations attributable to shareholders

* Adjusted income from continuing operations attributable to shareholders per common share (in EUR) - diluted (Adjusted EPS)

* EBITA

* Adjusted EBITA

* Adjusted EBITDA

* Free cash flow

* Net debt : group equity ratio, refer to [Fourth-quarter highlights](#tx1154249-philips-performance) and [Full-year highlights](#full-year-highlights)

For the definitions of the non-IFRS financial measures listed above, refer to chapter 12.3, Reconciliation of non-IFRS information, of the Annual Report 2021 and to the [Forward-looking statements and other important information](#tx20399129-forward-looking-statements-and-other-important-information).

#### Sales growth composition
in %

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Q4 2022 | Q4 2022 | Q4 2022 | Q4 2022 | January to December | January to December | January to December | January to December |
|  | nominal growth | consolidation changes | currency effects | comparable growth | nominal growth | consolidation changes | currency effects | comparable growth |
| **2022 versus 2021** |  |  |  |  |  |  |  |  |
| Diagnosis & Treatment | 12.0% | 0.0% | (6.7)% | 5.3% | 6.2% | 0.0% | (6.8)% | (0.7)% |
| Connected Care | 14.1% | (0.6)% | (8.4)% | 5.2% | (3.7)% | (0.1)% | (7.0)% | (10.8)% |
| Personal Health | 0.5% | 0.0% | (4.9)% | (4.4)% | 5.7% | 0.0% | (5.7)% | 0.1% |
|  **Philips Group** | **9.7%** | **0.2%** | **(6.5)%** | **3.4%** | **3.9%** | **(0.2)%** | **(6.5)%** | **(2.8)%** |

---

#### Adjusted income from continuing operations attributable to shareholders<sup>1)</sup>
in millions of EUR unless otherwise stated

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Q4 | Q4 | January to December | January to December |
| | 2021 | **2022** | 2021 | **2022** |
| Net income | 151 | (105) | 3323 | (1605) |
| Discontinued operations, net of income taxes | (12) | (8) | (2711) | (13) |
| **Income from continuing operations** | **139** | **(113)** | **612** | **(1618)** |
| Income from continuing operations attributable to non-controlling interests | 6 | - | (4) | (3) |
| **Income from continuing operations attributable to shareholders<sup>[1](#fntlw8s893p8g9g))</sup>** | **145** | **(113)** | **608** | **(1622)** |
| Adjustments for: |  |  |  |  |
| &nbsp;&nbsp;*Amortization and impairment of acquired intangible assets* | 69 | 104 | 322 | 363 |
| &nbsp;&nbsp;*Impairment of goodwill* |  | 27 | 15 | 1357 |
| &nbsp;&nbsp;*Restructuring and acquisition-related charges* | 26 | 117 | 95 | 202 |
| &nbsp;&nbsp;*Other items:* | 391 | 233 | 1069 | 925 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action provision* | *220* | *85* | *719* | *250* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action running remediation costs* | *46* | *63* | *94* | *210* |
| &nbsp;&nbsp;&nbsp;&nbsp;*R&D project impairments* |  |  |  | *134* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Portfolio realignment charges* |  |  |  | *109* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Impairment of assets in S&RC* |  |  |  | *39* |
| &nbsp;&nbsp;&nbsp;&nbsp; *Provision for a legal matter* |  | *60* |  | *60* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *74* |  | *94* | *59* |
| &nbsp;&nbsp;&nbsp;&nbsp;*Loss on divestment of business* | *6* |  | *76* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Remaining items* | *45* | *26* | *87* | *63* |
| &nbsp;&nbsp;Net finance expenses | (21) | - | (84) | (4) |
| &nbsp;&nbsp;Tax impact of adjusted items and tax only adjusting items | (104) | (7) | (527) | (376) |
| **Adjusted income from continuing operations attributable to shareholders<sup>[1](#fntlw8s893p8g9g))</sup>** | **507** | **360** | **1497** | **845** |
| **Earnings per common share:** |  |  |  |  |
| &nbsp;&nbsp;Income from continuing operations attributable to shareholders<sup>[1](#fntlw8s893p8g9g))</sup> per common share (in EUR) - diluted | 0.16 | (0.13) | 0.67 | (1.84) |
| &nbsp;&nbsp;Adjusted income from continuing operations attributable to shareholders<sup>[1](#fntlw8s893p8g9g))</sup> per common share (EUR) - diluted | 0.57 | 0.41 | 1.65 | 0.96 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

#### Reconciliation of Net income to Adjusted EBITA
in millions of EUR

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Philips Group | Diagnosis & Treatment | Connected Care | Personal Health | Other |
|  **Q4 2022** |  |  |  |  |  |
| Net income | (105) |  |  |  |  |
| Discontinued operations, net of income taxes | (8) |  |  |  |  |
| Income tax expense | 120 |  |  |  |  |
| Investments in associates, net of income taxes | 86 |  |  |  |  |
| Financial expenses | 92 |  |  |  |  |
| Financial income | (14) |  |  |  |  |
|  **Income from operations** | **171** | **158** | **(77)** | **173** | **(82)** |
| Amortization and impairment of acquired intangible assets | 104 | 49 | 49 | 4 | 2 |
| Impairment of goodwill | 27 | 27 |  |  |  |
| EBITA | 301 | 233 | (29) | 177 | (80) |
| Restructuring and acquisition-related charges | 117 | 25 | 43 | 10 | 38 |
| Other items: | 233 | 60 | 158 | (6) | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action provision* | *85* |  | *85* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action running remediation costs* | *63* |  | *63* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provision for a legal matter* | *60* | *60* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Remaining items* | *26* | *-* | *10* | *(6)* | *22* |
|  **Adjusted EBITA** | **651** | **318** | **172** | **180** | **(20)** |
|  **January to December 2022** |  |  |  |  |  |
| Net income | (1605) |  |  |  |  |
| Discontinued operations, net of income taxes | (13) |  |  |  |  |
| Income tax benefit | (113) |  |  |  |  |
| Investments in associates, net of income taxes | 2 |  |  |  |  |
| Financial expenses | 258 |  |  |  |  |
| Financial income | (58) |  |  |  |  |
|  **Income from operations** | **(1529)** | **404** | **(2246)** | **515** | **(202)** |
| Amortization and impairment of acquired intangible assets | 363 | 143 | 199 | 15 | 7 |
| Impairment of goodwill | 1357 | 27 | 1331 |  |  |
| EBITA | 192 | 573 | (716) | 531 | (196) |
| Restructuring and acquisition-related charges | 202 | 21 | 108 | 11 | 61 |
| Other items: | 925 | 180 | 703 | (4) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action provision* | *250* |  | *250* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action running remediation costs* | *210* |  | *210* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*R&D project impairments* | *134* | *120* | *12* | *3* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Portfolio realignment charges* | *109* |  | *109* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Impairment of assets in S&RC* | *39* |  | *39* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provision for a legal matter* | *60* | *60* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *59* |  | *59* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Remaining items* | *63* | *-* | *24* | *(6)* | *46* |
|  **Adjusted EBITA** | **1318** | **774** | **95** | **538** | **(89)** |
| **Q4 2021** |  |  |  |  |  |
| Net income | 151 |  |  |  |  |
| Discontinued operations, net of income taxes | (12) |  |  |  |  |
| Income tax benefit | (6) |  |  |  |  |
| Investments in associates, net of income taxes | 8 |  |  |  |  |
| Financial expenses | 56 |  |  |  |  |
| Financial income | (35) |  |  |  |  |
| **Income from operations** | **162** | **315** | **(314)** | **220** | **(59)** |
| Amortization and impairment of acquired intangible assets | 69 | 25 | 39 | 4 | 1 |
| EBITA | 230 | 339 | (275) | 223 | (57) |
| Restructuring and acquisition-related charges | 26 | (15) | 47 | (1) | (4) |
| Other items: | 391 | - | 373 |  | 18 |
| &nbsp;&nbsp;*Respironics field-action provision* | *220* |  | *220* |  |  |
| &nbsp;&nbsp;*Respironics field-action running remediation costs* | *46* |  | *46* |  |  |
| &nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *74* |  | *74* |  |  |
| &nbsp;&nbsp;*Loss on divestment of business* | *6* |  |  |  | *6* |
| &nbsp;&nbsp;*Remaining items* | *45* | *-* | *34* |  | *11* |
| **Adjusted EBITA** | **647** | **325** | **145** | **222** | **(44)** |
| **January to December 2021** |  |  |  |  |  |
| Net income | 3323 |  |  |  |  |
| Discontinued operations, net of income taxes | (2711) |  |  |  |  |
| Income tax benefit | (103) |  |  |  |  |
| Investments in associates, net of income taxes | 4 |  |  |  |  |
| Financial expenses | 188 |  |  |  |  |
| Financial income | (149) |  |  |  |  |
| **Income from operations** | **553** | **941** | **(722)** | **576** | **(242)** |
| Amortization and impairment of acquired intangible assets | 322 | 153 | 148 | 15 | 6 |
| Impairment of goodwill | 15 | 2 | 13 |  |  |
| EBITA | 890 | 1097 | (562) | 591 | (236) |
| Restructuring and acquisition-related charges | 95 | 7 | 93 | (1) | (5) |
| Other items: | 1069 | (32) | 965 | - | 136 |
| &nbsp;&nbsp;*Respironics field-action provision* | *719* | *-* | *719* |  | *-* |
| &nbsp;&nbsp;*Respironics field-action running remediation costs* | *94* |  | *94* |  |  |
| &nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *94* |  | *94* |  |  |
| &nbsp;&nbsp;*Loss on divestment of business* | *76* |  |  |  | *76* |
| &nbsp;&nbsp;*Remaining items* | *87* | *(32)* | *58* | *-* | *61* |
| **Adjusted EBITA** | **2054** | **1071** | **497** | **590** | **(105)** |

---

#### Reconciliation of Net income to Adjusted EBITDA
in millions of EUR

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Philips Group | Diagnosis & Treatment | Connected Care | Personal Health | Other |
|  **Q4 2022** |  |  |  |  |  |
| Net income | (105) |  |  |  |  |
| Discontinued operations, net of income taxes | (8) |  |  |  |  |
| Income tax expense | 120 |  |  |  |  |
| Investments in associates, net of income taxes | 86 |  |  |  |  |
| Financial expenses | 92 |  |  |  |  |
| Financial income | (14) |  |  |  |  |
| **Income from operations** | **171** | **158** | **(77)** | **173** | **(82)** |
| Depreciation, amortization and impairments of fixed assets | 381 | 125 | 107 | 32 | 116 |
| Impairment of goodwill | 27 | 27 |  |  |  |
| Restructuring and acquisition-related charges | 117 | 25 | 43 | 10 | 38 |
| Other items: | 233 | 60 | 158 | (6) | 22 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action provision* | *85* |  | *85* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action running remediation costs* | *63* |  | *63* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provision for a legal matter* | *60* | *60* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Remaining items* | *26* | *-* | *10* | *(6)* | *22* |
| Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items | (37) | - | (13) | - | (24) |
| **Adjusted EBITDA** | **891** | **395** | **218** | **208** | **70** |
|  **January to December 2022** |  |  |  |  |  |
| Net income | (1605) |  |  |  |  |
| Discontinued operations, net of income taxes | (13) |  |  |  |  |
| Income tax benefit | (113) |  |  |  |  |
| Investments in associates, net of income taxes | 2 |  |  |  |  |
| Financial expenses | 258 |  |  |  |  |
| Financial income | (58) |  |  |  |  |
| **Income from operations** | **(1529)** | **404** | **(2246)** | **515** | **(202)** |
| Depreciation, amortization and impairments of fixed assets | 1602 | 559 | 514 | 132 | 397 |
| Impairment of goodwill | 1357 | 27 | 1331 |  |  |
| Restructuring and acquisition-related charges | 202 | 21 | 108 | 11 | 61 |
| Other items: | 925 | 180 | 703 | (4) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action provision* | *250* |  | *250* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Respironics field-action running remediation costs* | *210* |  | *210* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*R&D project impairments* | *134* | *120* | *12* | *3* |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Portfolio realignment charges* | *109* |  | *109* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Impairment of assets in S&RC* | *39* |  | *39* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provision for a legal matter* | *60* | *60* |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *59* |  | *59* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;*Remaining items* | *63* | *-* | *24* | *(6)* | *46* |
| Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items | (252) | (135) | (84) | (3) | (30) |
| **Adjusted EBITDA** | **2305** | **1055** | **326** | **652** | **272** |
| **Q4 2021** |  |  |  |  |  |
| Net income | 151 |  |  |  |  |
| Discontinued operations, net of income taxes | (12) |  |  |  |  |
| Income tax benefit | (6) |  |  |  |  |
| Investments in associates, net of income taxes | 8 |  |  |  |  |
| Financial expenses | 56 |  |  |  |  |
| Financial income | (35) |  |  |  |  |
| **Income from operations** | **162** | **315** | **(314)** | **220** | **(59)** |
| Depreciation, amortization and impairments of fixed assets | 343 | 108 | 109 | 35 | 91 |
| Restructuring and acquisition-related charges | 26 | (15) | 47 | (1) | (4) |
| Other items: | 391 | - | 373 |  | 18 |
| &nbsp;&nbsp;*Respironics field-action provision* | *220* |  | *220* |  |  |
| &nbsp;&nbsp;*Respironics field-action running remediation costs* | *46* |  | *46* |  |  |
| &nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *74* |  | *74* |  |  |
| &nbsp;&nbsp;*Loss on divestment of business* | *6* |  |  |  | *6* |
| &nbsp;&nbsp;*Remaining items* | *45* | *-* | *34* |  | *11* |
| Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items | (17) | (1) | (16) | - | - |
| **Adjusted EBITDA** | **905** | **406** | **200** | **253** | **45** |
| **January to December 2021** |  |  |  |  |  |
| Net income | 3323 |  |  |  |  |
| Discontinued operations, net of income taxes | (2711) |  |  |  |  |
| Income tax benefit | (103) |  |  |  |  |
| Investments in associates, net of income taxes | 4 |  |  |  |  |
| Financial expenses | 188 |  |  |  |  |
| Financial income | (149) |  |  |  |  |
| **Income from operations** | **553** | **941** | **(722)** | **576** | **(242)** |
| Depreciation, amortization and impairments of fixed assets | 1323 | 459 | 382 | 131 | 350 |
| Impairment of goodwill | 15 | 2 | 13 |  |  |
| Restructuring and acquisition-related charges | 95 | 7 | 93 | (1) | (5) |
| Other items: | 1069 | (32) | 965 | - | 136 |
| &nbsp;&nbsp;*Respironics field-action provision* | *719* | *-* | *719* |  | *-* |
| &nbsp;&nbsp;*Respironics field-action running remediation costs* | *94* |  | *94* |  |  |
| &nbsp;&nbsp;*Provisions for quality actions in Connected Care* | *94* |  | *94* |  |  |
| &nbsp;&nbsp;*Loss on divestment of business* | *76* |  |  |  | *76* |
| &nbsp;&nbsp;*Remaining items* | *87* | *(32)* | *58* | *-* | *61* |
| Adding back impairment of fixed assets included in Restructuring and acquisition-related charges and Other items | (70) | (21) | (51) |  | 2 |
| **Adjusted EBITDA** | **2985** | **1358** | **680** | **706** | **241** |

---

#### Composition of free cash flow
in millions of EUR

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Q4 | Q4 | January to December | January to December |
| | 2021 | **2022** | 2021 | **2022** |
| Net cash provided by operating activities | 720 | 540 | 1629 | (173) |
| Net capital expenditures | (201) | (237) | (729) | (788) |
| &nbsp;&nbsp;*Purchase of intangible assets* | *(17)* | *(26)* | *(107)* | *(105)* |
| &nbsp;&nbsp;*Expenditures on development assets* | *(68)* | *(57)* | *(259)* | *(257)* |
| &nbsp;&nbsp;*Capital expenditures on property, plant and equipment* | *(129)* | *(164)* | *(397)* | *(444)* |
| &nbsp;&nbsp;*Proceeds from disposals of property, plant and equipment* | *13* | *10* | *33* | *18* |
| **Free cash flow** | **519** | **303** | **900** | **(961)** |

---

# Philips statistics
in millions of EUR unless otherwise stated

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| | Q1 | Q2 | Q3 | Q4 | **Q1** | **Q2** | **Q3** | **Q4** |
| Sales | 3827 | 4230 | 4156 | 4944 | 3918 | 4177 | 4310 | 5422 |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fnt2s5dno187qb1))</sup> | 9% | 9% | (8)% | (10)% | (4)% | (7)% | (5)% | 3% |
| &nbsp;&nbsp;Comparable order intake<sup>[2](#fnt2u5l1xjt0sbu))</sup> | (5)% | (15)% | 47% | 4% | 5% | 1% | (6)% | (8)% |
| Gross margin | 1487 | 1789 | 1973 | 1918 | 1511 | 1731 | 1730 | 2221 |
| &nbsp;&nbsp; *as a % of sales** | *38.9%* | *42.3%* | *47.5%* | *38.8%* | *38.6%* | *41.4%* | *40.1%* | *41.0%* |
| Selling expenses | (986) | (1056) | (1041) | (1175) | (1064) | (1111) | (1154) | (1280) |
| &nbsp;&nbsp; *as a % of sales** | *(25.8)%* | *(25.0)%* | *(25.0)%* | *(23.8)%* | *(27.2)%* | *(26.6)%* | *(26.8)%* | *(23.6)%* |
| G&A expenses | (173) | (138) | (164) | (124) | (155) | (146) | (175) | (195) |
| &nbsp;&nbsp; *as a % of sales** | *(4.5)%* | *(3.3)%* | *(3.9)%* | *(2.5)%* | *(4.0)%* | *(3.5)%* | *(4.1)%* | *(3.6)%* |
| R&D expenses | (424) | (470) | (437) | (475) | (495) | (490) | (615) | (504) |
| &nbsp;&nbsp; *as a % of sales** | *(11.1)%* | *(11.1)%* | *(10.5)%* | *(9.6)%* | *(12.6)%* | *(11.7)%* | *(14.3)%* | *(9.3)%* |
| Income from operations | (52) | 85 | 358 | 162 | (181) | 11 | (1529) | 171 |
| &nbsp;&nbsp; *as a % of sales** | *(1.4)%* | *2.0%* | *8.6%* | *3.3%* | *(4.6)%* | *0.3%* | *(35.5)%* | *3.2%* |
| Net income | 40 | 153 | 2980 | 151 | (151) | (20) | (1329) | (105) |
| Income from continuing operations attributable to shareholders<sup>[3](#fntjk0k988z0c8w))</sup> per common share in EUR - diluted | (0.04) | 0.07 | 0.47 | 0.16 | (0.17) | (0.03) | (1.50) | (0.13) |
| Adjusted income from continuing operations attributable to shareholders<sup>[3](#fntjk0k988z0c8w))</sup> per common share in EUR - diluted<sup>[1](#fnt2s5dno187qb1))</sup> | 0.28 | 0.40 | 0.40 | 0.57 | 0.15 | 0.14 | 0.25 | 0.41 |
| EBITA<sup>[1](#fnt2s5dno187qb1))</sup> | 61 | 173 | 426 | 230 | (107) | 92 | (94) | 301 |
| &nbsp;&nbsp; *as a % of sales** | *1.6%* | *4.1%* | *10.2%* | *4.6%* | *(2.7)%* | *2.2%* | *(2.2)%* | *5.5%* |
| Adjusted EBITA<sup>[1](#fnt2s5dno187qb1))</sup> | 362 | 532 | 512 | 647 | 243 | 216 | 209 | 651 |
| &nbsp;&nbsp; *as a % of sales** | *9.5%* | *12.6%* | *12.3%* | *13.1%* | *6.2%* | *5.2%* | *4.8%* | *12.0%* |
| Adjusted EBITDA<sup>[1](#fnt2s5dno187qb1))</sup> | 579 | 762 | 739 | 905 | 488 | 461 | 466 | 891 |
| &nbsp;&nbsp; *as a % of sales** | *15.1%* | *18.0%* | *17.8%* | *18.3%* | *12.5%* | *11.0%* | *10.8%* | *16.4%* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. <sup>2)</sup> Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. <sup>3)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Philips statistics** in millions of EUR unless otherwise stated

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | 2021 | 2021 | 2021 | 2021 | 2022 | 2022 | 2022 | 2022 |
| | January-March | January-June | January-September | January-December | **January-March** | **January-June** | **January-September** | **January-December** |
| Sales | 3827 | 8057 | 12212 | 17156 | 3918 | 8095 | 12405 | 17827 |
| &nbsp;&nbsp;Comparable sales growth<sup>[1](#fntrkwda3i863a7))</sup> | 9% | 9% | 3% | (1)% | (4)% | (5)% | (5)% | (3)% |
| &nbsp;&nbsp;Comparable order intake <sup>[2](#fnt62cji849p834))</sup> | (5)% | (11)% | 4% | 4% | 5% | 3% | (1)% | (3)% |
| Gross margin | 1487 | 3277 | 5250 | 7168 | 1511 | 3243 | 4973 | 7194 |
| &nbsp;&nbsp; *as a % of sales** | *38.9%* | *40.7%* | *43.0%* | *41.8%* | *38.6%* | *40.1%* | *40.1%* | *40.4%* |
| Selling expenses | (986) | (2042) | (3083) | (4258) | (1064) | (2175) | (3329) | (4609) |
| &nbsp;&nbsp; *as a % of sales** | *(25.8)%* | *(25.3)%* | *(25.2)%* | *(24.8)%* | *(27.2)%* | *(26.9)%* | *(26.8)%* | *(25.9)%* |
| G&A expenses | (173) | (311) | (475) | (599) | (155) | (301) | (476) | (671) |
| &nbsp;&nbsp; *as a % of sales** | *(4.5)%* | *(3.9)%* | *(3.9)%* | *(3.5)%* | *(4.0)%* | *(3.7)%* | *(3.8)%* | *(3.8)%* |
| R&D expenses | (424) | (894) | (1331) | (1806) | (495) | (985) | (1600) | (2103) |
| &nbsp;&nbsp; *as a % of sales** | *(11.1)%* | *(11.1)%* | *(10.9)%* | *(10.5)%* | *(12.6)%* | *(12.2)%* | *(12.9)%* | *(11.8)%* |
| Income from operations | (52) | 33 | 391 | 553 | (181) | (170) | (1700) | (1529) |
| &nbsp;&nbsp; *as a % of sales** | *(1.4)%* | *0.4%* | *3.2%* | *3.2%* | *(4.6)%* | *(2.1)%* | *(13.7)%* | *(8.6)%* |
| Net income | 40 | 192 | 3173 | 3323 | (151) | (171) | (1500) | (1605) |
| Income from continuing operations attributable to shareholders<sup>[3](#fnt3qgfydc50l80))</sup> per common share in EUR - diluted | (0.04) | 0.03 | 0.51 | 0.67 | (0.17) | (0.20) | (1.72) | (1.84) |
| Adjusted income from continuing operations attributable to shareholders<sup>[3](#fnt3qgfydc50l80))</sup> per common share in EUR - diluted<sup>[1](#fntrkwda3i863a7))</sup> | 0.28 | 0.69 | 1.08 | 1.65 | 0.15 | 0.30 | 0.55 | 0.96 |
| EBITA<sup>[1](#fntrkwda3i863a7))</sup> | 61 | 234 | 660 | 890 | (107) | (15) | (109) | 192 |
| &nbsp;&nbsp; *as a % of sales** | *1.6%* | *2.9%* | *5.4%* | *5.2%* | *(2.7)%* | *(0.2)%* | *(0.9)%* | *1.1%* |
| Adjusted EBITA<sup>[1](#fntrkwda3i863a7))</sup> | 362 | 894 | 1406 | 2054 | 243 | 459 | 667 | 1318 |
| &nbsp;&nbsp; *as a % of sales** | *9.5%* | *11.1%* | *11.5%* | *12.0%* | *6.2%* | *5.7%* | *5.4%* | *7.4%* |
| Adjusted EBITDA<sup>[1](#fntrkwda3i863a7))</sup> | 579 | 1341 | 2080 | 2985 | 488 | 948 | 1414 | 2305 |
| &nbsp;&nbsp; *as a % of sales** | *15.1%* | *16.6%* | *17.0%* | *17.4%* | *12.5%* | *11.7%* | *11.4%* | *12.9%* |
| Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands) | 905289 | 912734 | 910306 | 870182 | 869298 | 885316 | 885348 | 881481 |
| Shareholders' equity per common share in EUR | 13.80 | 13.10 | 16.00 | 16.59 | 16.64 | 16.63 | 16.31 | 15.03 |
| Net debt : group equity ratio<sup>[1](#fntrkwda3i863a7))</sup> | 34:66 | 36:64 | 21:79 | 24:76 | 28:72 | 31:69 | 34:66 | 35:65 |
| Total employees | 77343 | 77084 | 77746 | 78189 | 78548 | 78831 | 79097 | 77233 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1)</sup> Non-IFRS financial measure. Refer to Reconciliation of non-IFRS information. <sup>2)</sup> Comparable order intake is presented when discussing the Philips Group's performance. For the definition of this measure, refer to chapter 12.4, Other Key Performance Indicators, of the Annual Report 2021. <sup>3)</sup> Shareholders refers to shareholders of Koninklijke Philips N.V.

#© 2023 Koninklijke Philips N.V.
All rights reserved.

https://www.philips.com/investorrelations

![Philips shield](visual0002.jpg)